Logo image of NYXH

NYXOAH SA (NYXH) Stock Fundamental Analysis

NASDAQ:NYXH - Nasdaq - BE0974358906 - Common Stock - Currency: USD

10.347  -0.05 (-0.51%)

Fundamental Rating

3

Taking everything into account, NYXH scores 3 out of 10 in our fundamental rating. NYXH was compared to 189 industry peers in the Health Care Equipment & Supplies industry. NYXH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

NYXH had negative earnings in the past year.
In the past year NYXH has reported a negative cash flow from operations.
In the past 5 years NYXH always reported negative net income.
NYXH had a negative operating cash flow in each of the past 5 years.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

NYXH's Return On Assets of -37.11% is in line compared to the rest of the industry. NYXH outperforms 40.11% of its industry peers.
NYXH's Return On Equity of -50.60% is in line compared to the rest of the industry. NYXH outperforms 49.20% of its industry peers.
Industry RankSector Rank
ROA -37.11%
ROE -50.6%
ROIC N/A
ROA(3y)-24.12%
ROA(5y)-27.74%
ROE(3y)-29.54%
ROE(5y)-65.78%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

NYXH's Gross Margin of 61.75% is fine compared to the rest of the industry. NYXH outperforms 62.03% of its industry peers.
In the last couple of years the Gross Margin of NYXH has grown nicely.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.08%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYXH has more shares outstanding
The number of shares outstanding for NYXH has been increased compared to 5 years ago.
Compared to 1 year ago, NYXH has a worse debt to assets ratio.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

NYXH has an Altman-Z score of 3.37. This indicates that NYXH is financially healthy and has little risk of bankruptcy at the moment.
NYXH has a Altman-Z score of 3.37. This is in the better half of the industry: NYXH outperforms 70.59% of its industry peers.
NYXH has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
NYXH has a Debt to Equity ratio of 0.21. This is comparable to the rest of the industry: NYXH outperforms 54.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 3.37
ROIC/WACCN/A
WACC7.53%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

NYXH has a Current Ratio of 5.28. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
NYXH has a better Current ratio (5.28) than 78.07% of its industry peers.
A Quick Ratio of 4.95 indicates that NYXH has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.95, NYXH belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 4.95
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for NYXH have decreased by -2.14% in the last year.
The Revenue has grown by 32.65% in the past year. This is a very strong growth!
Measured over the past years, NYXH shows a very strong growth in Revenue. The Revenue has been growing by 297.94% on average per year.
EPS 1Y (TTM)-2.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.47%
Revenue 1Y (TTM)32.65%
Revenue growth 3Y297.94%
Revenue growth 5YN/A
Sales Q2Q%29.71%

3.2 Future

The Earnings Per Share is expected to grow by 0.51% on average over the next years.
The Revenue is expected to grow by 135.08% on average over the next years. This is a very strong growth
EPS Next Y-9.57%
EPS Next 2Y-6.59%
EPS Next 3Y0.51%
EPS Next 5YN/A
Revenue Next Year24.94%
Revenue Next 2Y152.69%
Revenue Next 3Y151.63%
Revenue Next 5Y135.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.59%
EPS Next 3Y0.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYXOAH SA

NASDAQ:NYXH (2/21/2025, 8:00:01 PM)

10.347

-0.05 (-0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners32.66%
Inst Owner Change-96.47%
Ins Owners20.26%
Ins Owner ChangeN/A
Market Cap387.29M
Analysts81.43
Price Target15.74 (52.12%)
Short Float %0.32%
Short Ratio1.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.42%
Min EPS beat(2)-3.56%
Max EPS beat(2)0.72%
EPS beat(4)3
Avg EPS beat(4)0.17%
Min EPS beat(4)-3.56%
Max EPS beat(4)2.33%
EPS beat(8)4
Avg EPS beat(8)-11.67%
EPS beat(12)7
Avg EPS beat(12)-3.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33%
Min Revenue beat(2)-55.92%
Max Revenue beat(2)-10.09%
Revenue beat(4)1
Avg Revenue beat(4)-17.48%
Min Revenue beat(4)-55.92%
Max Revenue beat(4)4.47%
Revenue beat(8)1
Avg Revenue beat(8)-28.22%
Revenue beat(12)1
Avg Revenue beat(12)-36.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.16%
PT rev (3m)4.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.72%
EPS NY rev (3m)1.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 72.82
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 6.71
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS0.14
BVpS2.93
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.11%
ROE -50.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.75%
FCFM N/A
ROA(3y)-24.12%
ROA(5y)-27.74%
ROE(3y)-29.54%
ROE(5y)-65.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.08%
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.42%
Cap/Sales 18.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 4.95
Altman-Z 3.37
F-Score2
WACC7.53%
ROIC/WACCN/A
Cap/Depr(3y)80.06%
Cap/Depr(5y)68.52%
Cap/Sales(3y)86.21%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.47%
EPS Next Y-9.57%
EPS Next 2Y-6.59%
EPS Next 3Y0.51%
EPS Next 5YN/A
Revenue 1Y (TTM)32.65%
Revenue growth 3Y297.94%
Revenue growth 5YN/A
Sales Q2Q%29.71%
Revenue Next Year24.94%
Revenue Next 2Y152.69%
Revenue Next 3Y151.63%
Revenue Next 5Y135.08%
EBIT growth 1Y-18.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.88%
EBIT Next 3Y-6.85%
EBIT Next 5Y7.62%
FCF growth 1Y-88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.38%
OCF growth 3YN/A
OCF growth 5YN/A